| Original language | English (US) |
|---|---|
| Pages (from-to) | 1777-1779 |
| Number of pages | 3 |
| Journal | Journal of the American Academy of Dermatology |
| Volume | 83 |
| Issue number | 6 |
| DOIs | |
| State | Published - Dec 2020 |
ASJC Scopus subject areas
- Dermatology
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of the American Academy of Dermatology, Vol. 83, No. 6, 12.2020, p. 1777-1779.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Opioid prescribing in adults with and without psoriasis
AU - Noe, Megan H.
AU - Shin, Daniel B.
AU - Wehner, Mackenzie R.
AU - Margolis, David J.
AU - Gelfand, Joel M.
N1 - Funding Information: Funding sources: Supported in part by a Center Core Center of Excellence Grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (P30 AR069589). Dr Noe is supported by a Career Development Award (K23-AR073932) from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. Dr Wehner was supported by a National Institute of Arthritis and Musculoskeletal and Skin Diseases/National Institutes of Health Dermatology Research Training grant (T32 AR7465; principal investigator: Sarah E. Millar).Disclosure: Dr Margolis receives research funding as the principal investigator via the Trustees of the University of Pennsylvania (R01-AR060962, R01- AR070873, and R01-DK116199) and from the National Institutes of Health and Valeant Pharmaceuticals (PEER study) and Sunovion Pharmaceuticals (none of this funding was used for this study), and he has consulting activities primarily as a member of data monitoring boards or scientific advisory boards with Leo, Johnson and Johnson, Pfizer, Sanofi, Kerecis, and Cell Constructs (none of these activities are associated with the outcomes of this study). Dr Gelfand served as a consultant for Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Janssen Biologics, Novartis Corp, UCB (Data Safety and Monitoring Board), Sanofi, and Pfizer Inc, receiving honoraria; receives research grants (to the Trustees of the University of Pennsylvania) from AbbVie, Janssen, Novartis Corp, Celgene, Ortho Dermatologics, and Pfizer Inc; and received payment for continuing medical education work related to psoriasis that was supported indirectly by Lilly, Ortho Dermatologic, and Novartis. Drs Noe, Shin, and Wehner have no conflicts of interest to declare. Funding Information: Funding sources: Supported in part by a Center Core Center of Excellence Grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases ( P30 AR069589 ). Dr Noe is supported by a Career Development Award ( K23-AR073932 ) from the National Institute of Arthritis and Musculoskeletal and Skin Diseases . Dr Wehner was supported by a National Institute of Arthritis and Musculoskeletal and Skin Diseases / National Institutes of Health Dermatology Research Training grant ( T32 AR7465 ; principal investigator: Sarah E. Millar).
PY - 2020/12
Y1 - 2020/12
UR - http://www.scopus.com/inward/record.url?scp=85092444205&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092444205&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2020.03.080
DO - 10.1016/j.jaad.2020.03.080
M3 - Article
C2 - 32246971
AN - SCOPUS:85092444205
SN - 0190-9622
VL - 83
SP - 1777
EP - 1779
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 6
ER -